// App-Quantinova.ai

62 : Efficacy and Safety of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Treatment‐Naive Patients with Chronic HCV Genotype 3: An Integrated Phase 2/3 Analysis

Researchers

Presenter

  • Steven L. Flamm

Principal Investigators

  • Stanley Wang

  • David J. Mutimer

  • Jrgen K. Rockstroh

  • Yves J. Horsmans

  • Paul Y. Kwo

  • Ola Weiland

  • Erica Villa

  • Jeong Heo

  • Edward J. Gane

  • Stephen D. Ryder

  • Tania M. Welzel

  • Teresa Ng

  • Sandra S. Lovell

  • Ran Liu

  • Preethi Krishnan

  • Sarah Kopecky-Bromberg

  • Armen Asatryan

  • Roger Trinh

  • Federico J. Mensa

Medical Centers

  • Northwestern University, Feinberg School of Medicine, Chicago, IL

  • Denver VA Medical Center, Denver, CO

  • AbbVie, Inc., North Chicago, IL

  • Queen Elizabeth Hospital and NIHR Liver Biomedical Research Unit, Birmingham, United Kingdom

  • Universitatsklinikum Bonn, Bonn, Germany

  • Universite Catholique de Louvain, Bruxelles, Belgium

  • Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, United States

  • Rheumatology Unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden

  • Univeristy of Modena and Reggio Emilia, Modena, Italy

  • Department of Internal Medicine, College of Medicine, Pusan National University and Medical Research Institute, Busan, Korea (the Republic of)

  • Auckland City Hospital, Auckland, New Zealand

  • Nottingham Digestive Diseases Biomedical Research Unit, Nottingham, United Kingdom

  • Goethe University, Frankfurt, Germany

Locations

  • United States

  • United Kingdom

  • Germany

  • Belgium

  • Sweden

  • Italy

  • Republic of South Korea

  • New Zealand

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Cirrhosis

Biomarkers

  • N/A

Drug/Treatment

  • Glecaprevir and Pibrentasvir

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II/III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved